@article{1894a62f4f534b94a36477f4a1791a58,
title = "Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review",
abstract = "A new cardiometabolic-based chronic disease (CMBCD) model is presented that provides a basis for early and sustainable, evidence-based therapeutic targeting to promote cardiometabolic health and mitigate the development and ravages of cardiovascular disease. In the first part of this JACC State-of-the-Art Review, a framework is presented for CMBCD, focusing on 3 primary drivers (genetics, environment, and behavior) and 2 metabolic drivers (adiposity and dysglycemia) with applications to 3 cardiovascular endpoints (coronary heart disease, heart failure, and atrial fibrillation). Specific mechanistic pathways are presented configuring early primary drivers with subsequent adiposity, insulin resistance, β-cell dysfunction, and metabolic syndrome, leading to cardiovascular disease. The context for building this CMBCD model is to expose actionable targets for prevention to achieve optimal cardiovascular outcomes. The tactical implementation of this CMBCD model is the subject of second part of this JACC State-of-the-Art Review.",
keywords = "adipokines, adiposity, atherosclerosis, atrial fibrillation, cardiomyopathy, cardiovascular, chronic disease, dysglycemia, insulin resistance, obesity, type 2 diabetes",
author = "Mechanick, {Jeffrey I.} and Farkouh, {Michael E.} and Newman, {Jonathan D.} and Garvey, {W. Timothy}",
note = "Funding Information: Dr. Mechanick has received honoraria for lectures from Abbott Nutrition International. Dr. Farkouh has received research grants from Amgen, Novartis, and Novo Nordisk. Dr. Newman has received research grants from the National Institutes of Health National Heart, Lung, and Blood Institute K23HL125991; and has received honoraria from Creative Educational Concepts. Dr. Garvey has served on ad hoc advisory boards for Sanofi, Novo Nordisk, Boehringer Ingelheim, Gilead, Amgen, BOYDSense, and the American Medical Group Association; and has conducted research sponsored by the University of Alabama at Birmingham funded by Sanofi, Merck/Pfizer, Novo Nordisk, AstraZeneca, and Lexicon. Funding Information: Dr. Mechanick has received honoraria for lectures from Abbott Nutrition International. Dr. Farkouh has received research grants from Amgen, Novartis, and Novo Nordisk. Dr. Newman has received research grants from the National Institutes of Health National Heart, Lung, and Blood Institute K23HL125991; and has received honoraria from Creative Educational Concepts. Dr. Garvey has served on ad hoc advisory boards for Sanofi, Novo Nordisk, Boehringer Ingelheim, Gilead, Amgen, BOYDSense, and the American Medical Group Association; and has conducted research sponsored by the University of Alabama at Birmingham funded by Sanofi, Merck/Pfizer, Novo Nordisk, AstraZeneca, and Lexicon. Publisher Copyright: {\textcopyright} 2020 American College of Cardiology Foundation",
year = "2020",
month = feb,
day = "11",
doi = "10.1016/j.jacc.2019.11.044",
language = "English",
volume = "75",
pages = "525--538",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "5",
}